☆ 4.5 Letter

Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells

CLINICAL AND EXPERIMENTAL ALLERGY (2019)

Get Full Text
Add to Collection

Journal

CLINICAL AND EXPERIMENTAL ALLERGY
Volume 49, Issue 2, Pages 255-257

Publisher

WILEY
DOI: 10.1111/cea.13304

Keywords

-

Categories

Allergy Immunology

Funding

  1. Novartis Pharma AG, Basel, Switzerland

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.